ProVerum Medical

ProVerum Medical is a private, venture-backed medical device startup developing the ProVee System, a first-line interventional therapy for BPH. The company's core innovation is a universally sized, 3D-geometry nitinol stent that engages the prostate's anatomy to provide rapid, reversible relief of urinary obstruction. With pivotal clinical studies completed in the US, Canada, and Ireland, ProVerum is positioning its atraumatic, retrieval-friendly device as a potential paradigm shift in the early interventional treatment of BPH, targeting a massive and growing global market dominated by drug therapies and more invasive surgical options.

Proprietary nitinol stent with 3D anatomical geometry designed for universal fit and reversible implantation. Platform includes a low-profile delivery system and portable video processing unit for in-office deployment.

ProVerum competes in the BPH device market against large players like Boston Scientific (Rezūm, TURP), Olympus, and Medtronic, as well as other MIST technologies (UroLift, iTind). Its primary differentiation is reversibility and positioning as a first-line intervention, rather than a last resort before major surgery.